Taysha Gene Therapies
TSHA
119 hedge funds and large institutions have $316M invested in Taysha Gene Therapies in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 46 increasing their positions, 16 reducing their positions, and 18 closing their positions.
188% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 16
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
11% more funds holding
Funds holding: 107 → 119 (+12)
10% more call options, than puts
Call options by funds: $55K | Put options by funds: $50K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.93% less ownership
Funds ownership: 78.53% → 76.6% (-1.9%)
11% less capital invested
Capital invested by funds: $354M → $316M (-$38.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.17M |
| 2 |
BlackRock
New York
|
+$3.9M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.42M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.41M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$9.75M |
| 2 |
RI
RTW Investments
New York
|
-$8.46M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.56M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$3.89M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.67M |
TSHA Hedge Fund Activity: Q3 2024 in Review
119 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q3 2024, worth a combined $316M — down 11% from $354M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new TSHA positions and 18 closed out — a net gain of 12 holders — while 46 added to existing stakes and 16 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $6.17M. The largest seller was Artal Group, exiting entirely with an estimated $9.75M sold.
- 119 institutional investors held Taysha Gene Therapies (TSHA) as of Q3 2024, up from 107 in Q2 2024.
- Funds reported $316M of Taysha Gene Therapies stock for Q3 2024, down 11% quarter-over-quarter.
- 30 funds opened new Taysha Gene Therapies positions in Q3 2024 and 18 closed out, a net change of +12 holders.
- The largest Taysha Gene Therapies buyer in Q3 2024 was Citadel Advisors, an estimated $6.17M added.
- The largest Taysha Gene Therapies seller in Q3 2024 was Artal Group, an estimated $9.75M sold.
Based on aggregated 13F filings for Q3 2024.